SOD1 and amyotrophic lateral sclerosis: Finally, CRISPR-based approaches downregulating SOD1 do not distinguish between mutant and wild-type genes,44,46 but they target regions that are not reported to contain ALS-causing mutations to provide a universal therapy for individuals with ALS harboring mutations in SOD1. However, for the same reason, these strategies could be associated with potentially dangerous SOD1 downregulation, which needs to be taken into account because a homozygous SOD1-truncating mutation abolishing SOD1 activity has been reported to lead to progressive loss of motor activity in an infant.48